TNF Pharmaceuticals, Inc.
TNFA
$0.1196
-$0.0104-8.00%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -49.45% | -38.54% | -22.47% | -11.90% | 56.06% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -51.80% | -47.07% | -25.43% | -11.44% | 33.33% |
| Operating Income | 51.80% | 47.07% | 25.43% | 11.44% | -33.33% |
| Income Before Tax | -19.50% | -483.98% | -339.60% | -34.82% | 2.37% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -19.50% | -483.98% | -339.60% | -34.82% | 2.37% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -19.50% | -483.98% | -339.60% | -34.82% | 2.37% |
| EBIT | 51.80% | 47.07% | 25.43% | 11.44% | -33.33% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 22.98% | -124.65% | -150.31% | -4.72% | 4.93% |
| Normalized Basic EPS | 2.80% | -289.62% | -162.66% | 23.74% | 35.94% |
| EPS Diluted | 33.62% | -75.62% | -96.68% | -19.40% | -10.31% |
| Normalized Diluted EPS | 28.06% | -114.90% | -73.01% | 1.50% | 13.45% |
| Average Basic Shares Outstanding | 86.72% | 57.37% | 51.61% | 43.28% | 30.56% |
| Average Diluted Shares Outstanding | -1.95% | -21.86% | -27.75% | 158.43% | 148.62% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | 0.59% | 0.69% | -- | -- | -- |